Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Panbela Therapeutics, Inc.

Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Pricing of Approximately $15 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Announces Pricing of Approximately $6 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Tickers PBLA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.